Prostaglandin

In the clinical diagnosis and treatment of cardiovascular diseases, reproductive system diseases and ophthalmic diseases, prostaglandins are an important treatment option with a wide range of physiological activities. As endogenous unsaturated fatty acid derivatives, these drugs exert multiple physiological effects such as regulating vasomotion, smooth muscle contraction, inflammatory response and platelet aggregation by binding to G protein-coupled prostaglandin receptors. At present, they have been widely used in the treatment of pulmonary arterial hypertension, labor induction, postpartum hemorrhage, glaucoma, male erectile dysfunction and other diseases, covering multiple applicable groups such as adults and pregnant and lying-in women, and are a key category of drugs in the clinical pathways of multiple departments.

The global market size of prostaglandins has maintained a steady growth trend in recent years. In 2023, the market size has exceeded 12 billion US dollars, with a compound annual growth rate of approximately 6.8%. Due to the complex synthesis process and high difficulty in chiral control of prostaglandins, the global market supply is highly concentrated, with leading enterprises accounting for more than 70% of the market share. The domestic market is still in the stage of import substitution. With the advancement of the centralized drug procurement policy for preparations and the technological breakthroughs of local enterprises, the market share of domestic prostaglandin APIs is increasing year by year, and the localization rate was close to 35% in 2023.

Most of the original research and development enterprises of prostaglandins are multinational pharmaceutical companies such as Pfizer, Actelion and Santen Pharmaceutical. The patent expiration dates of varieties for different sub-indications are concentrated between 2015 and 2028. Common dosage forms include injections, eye drops, gels, etc. A number of mainstream varieties have been included in the Chinese *Catalogue of Reference Preparations for Chemical Drugs* and the FDA Reference Preparations Catalogue. Up to now, 12 prostaglandin-related API varieties in China have obtained A status label through CDE registration, and the corresponding approved domestic preparation varieties exceed 30, which can meet most of the domestic clinical drug demand. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO provides a full set of impurity reference standards for prostaglandin APIs. Most of the products are in stock. Orders for in-stock products placed before 16:00 will be shipped on the same day. The products meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can provide stable and reliable reference standard support for API research and development, quality research and consistency evaluation work.